<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764305</url>
  </required_header>
  <id_info>
    <org_study_id>registration in progress</org_study_id>
    <nct_id>NCT04764305</nct_id>
  </id_info>
  <brief_title>Liver Disease, Myocardial Fibrosis and Collaterals in the Adult Fontan Patient a Metabolomics and Proteomics Approach</brief_title>
  <official_title>Liver Disease, Myocardial Fibrosis and Collaterals in the Adult Fontan Patient - a Metabolomics and Proteomics Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Diabetes Center North Rhine-Westphalia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Austrian Science Fund (FWF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Out objective is to identify the mechanisms that promote hepatic and myocardial fibrosis, and&#xD;
      collateral vessel formation in patients with complex congenital heart disease and Fontan&#xD;
      circulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In their prior works the investigators could show that there is evidence of a proinflammatory&#xD;
      condition in a certain subgroup of patients with complex congenital heart disease and a so&#xD;
      called Fontan circulation. Those patients are also prone to develop hepatic and myocardial&#xD;
      fibrosis as well as to reveal collateral vessel formation. The investigators' hypothesis is&#xD;
      that this pro-inflammatory condition is not only reflecting pre-stages of one or more of&#xD;
      those 3 issues, but that this is also a main driving mechanism to develop and hepatic or&#xD;
      myocardial fibrosis and collateral vessels.&#xD;
&#xD;
      The objective of the here proposed study thus is to identify the mechanisms that promote&#xD;
      hepatic and myocardial fibrosis, and collateral vessel formation, and thus provide insight&#xD;
      into the determination of those Fontan patients that tend to develop those conditions. The&#xD;
      investigators attempt to link the issues of hepatic and myocardial fibrosis and collateral&#xD;
      vessel formation by directing our focus on the phospholipid, amino acid and bile acid&#xD;
      metabolism and on cell surface markers, cytokines, and chemokines as surrogates for&#xD;
      proinflammatory, profibrotic and proangiogenic conditions.&#xD;
&#xD;
      This study would thereby allow for a deeper insight into Fontan pathophysiology and sequelae&#xD;
      and might provide first steps towards the identification of possible diagnostic or eventually&#xD;
      therapeutic targets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants</measure>
    <time_frame>July 2021-December 2023</time_frame>
    <description>When aspired number of participants is reached</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Patient Participation</condition>
  <condition>Heart Defects, Congenital</condition>
  <condition>Liver Diseases</condition>
  <condition>Collateral Circulation, Any Site</condition>
  <condition>Myocardial Fibrosis</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with Fontan circulation. No intervention planned (observational study)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy, biventricular controls. No intervention planned (observational study)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with Fontan circulation, see inclusion criteria. Healthy, biventrucal age-&#xD;
        and sex-matched controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  written informed consent of participants&#xD;
&#xD;
          -  age at testing of ≥18 years&#xD;
&#xD;
          -  8 h fasting before blood sampling&#xD;
&#xD;
          -  Fontan circulation (patients)&#xD;
&#xD;
          -  biventricular heart without structural or functional abnormality (controls)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Protein losing enteropathy (PLE) (patients are defined as &quot;PLE positive&quot; if there&#xD;
             is/are serum protein &lt;5g/dL and serum albumin &lt;3g/dL (duration for more than 3 months&#xD;
             and exclusion of other causes for hypoproteinemia) and documented enteric protein&#xD;
             loss: faecal alpha-1-antitrypsin ≥400 µg/g&#xD;
&#xD;
          -  medication directly affecting metabolic state, such as cholesterol-lowering agents, or&#xD;
             haemodynamic state, such as beta-blockers or sildenafil, with the exception of&#xD;
             angiotensin converting enzyme inhibitors, diuretics, and anticoagulants&#xD;
&#xD;
          -  atrial or ventricular arrhythmia&#xD;
&#xD;
          -  coronary artery disease (history of myocardial infarction, myocardial&#xD;
             revascularisation, percutaneous coronary intervention, or coronary artery bypass&#xD;
             surgery)&#xD;
&#xD;
          -  any metabolic disease, such as diabetes mellitus&#xD;
&#xD;
          -  malignancy&#xD;
&#xD;
          -  obesity (body mass index (BMI) &gt;25 kg/m2)&#xD;
&#xD;
          -  underweight (BMI &lt; 18 kg/m2)&#xD;
&#xD;
          -  renal disease&#xD;
&#xD;
          -  inflammatory disease such as acute or chronic infection&#xD;
&#xD;
          -  myeloproliferative disorder&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  malnourishment&#xD;
&#xD;
          -  mental handicap not allowing valid consent to participation in the study or CMR&#xD;
&#xD;
          -  need of sedation or general anesthesia for CMR&#xD;
&#xD;
          -  typical contraindications for performing CMR such as metal-containing mechanical or&#xD;
             electronic implants&#xD;
&#xD;
          -  claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University Innsbruck</investigator_affiliation>
    <investigator_full_name>OÄ Dr. Miriam Michel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Fontan</keyword>
  <keyword>congenital heart disease</keyword>
  <keyword>inflammation</keyword>
  <keyword>Fontan-associated liver disease</keyword>
  <keyword>Myocardial fibrosis</keyword>
  <keyword>Collateral vessel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

